News

BREAKING NEWS – the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Click here to read the full release the Society of Nuclear Medicine and Molecular Imaging and from Josh Mailman, chairman of the Society’s Patient Advocacy Advisory Board and president of the NorCal CarciNET Community.

ucsf hdfccc logo 4color2014 Neuroendocrine Tumor Patient Conference
Hosted by: NorCal CarciNET Community & UCSF Helen Diller Family Comprehensive Cancer Center

Sunday, January 19, 2014 - 9:00 am to 4:00 pm

NEW Location Krutch Theater (Clark-Kerr) on the UC Berkeley Campus
2601 Warring St., Bldg. 14, Clark Kerr Campus, Berkeley, CA 94720

Please join us for a day of discussion on the latest developments in neuroendocrine tumor (NET) research and treatment. Topics will range from discovery and diagnosis through treatment and living with cancer and feature experts from around the world. Open to both patients, caregivers and those interested in NETs.

Caring for Carcinoid Foundation and Stanford Cancer Center
Neuroendocrine Tumor Patient Education Conference
Stanford University ~ Arrillaga Alumni Center, McCaw Hall
October 12th, 2013

To Download presentations from this event please click here.

1-IMAG0275During the month of October, Josh Mailman, President of NorCal CarciNet Community made two trips to Washington D.C. on behalf of the NET Community. During his first trip of the month Josh attended the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Patient Advocate Advisory meeting which he chairs.

On Sunday June 9th, 2013 the Society of Nuclear Medicine and Molecular Imaging Patient Advocacy Advisory Board (PAAB) held a patient education day at their annual meeting. The patient program is designed for patient and those who support them as well as the general public to learn more about molecular imaging and treatments. The day included a special NETs breakout in the afternoon covering specific imaging and treatments available for those with NETS delivered by international experts. NorCal CarciNet's Josh Mailman is the current chair of the PAAB and gave a keynote address at the conference.

We have linked the Agenda below to the online presentation. We hope you find the information useful.